GLPG4716 not checked

Molecure S.A. · Lakefront Biotherapeutics NV · OATD-01

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Pulmonary Sarcoidosis
Main trialPhase 2
“This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.”In the company’s words, NCT06205121 on ClinicalTrials.gov
Other names
OATD-01

Other drugs for Pulmonary Sarcoidosis

All 3 drugs for Pulmonary Sarcoidosis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Aug 2027 Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
Phase 1Completed 13 Nov 2021 Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
Phase 1Completed 9 May 2022 Drug-drug Interaction Study with GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow GLPG4716

Following is part of Solo: you see every change to GLPG4716 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in